Bioxytran (BIXT) Capital Expenditures (2012 - 2013)
Bioxytran (BIXT) posted Capital Expenditures of $164418.0 for Q3 2013, up 978.43% sequentially from $15246.0 in Q3 2012, and up 978.43% YoY from $15246.0 in Q3 2012.
Bioxytran (BIXT) Capital Expenditures (2012 - 2013) Analysis & Trends
Bioxytran has reported Capital Expenditures for 2 years, with the latest figure at $164418.0 in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 164,418.00 |
| Sep 30, 2013 | 164,418.00 |
| Sep 30, 2012 | 15,246.00 |
| Sep 30, 2012 | 15,246.00 |